Literature DB >> 7904252

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

J Camps1, S Crisóstomo, M García-Granero, J I Riezu-Boj, M P Civeira, J Prieto.   

Abstract

Pretreatment variables that could predict the response of chronic hepatitis C to interferon alfa treatment have not been fully assessed. Eighteen baseline variables were evaluated in a series of 100 consecutive patients treated with a 12 month course of interferon alfa. For the purposes of this study, response was defined as the return to normal of aminotransferase activities before the third month of treatment. Seventy per cent of the patients responded to treatment. Six variables were associated with an increased likelihood of response assessed by univariate analysis. With stepwise multiple regression analysis assessment, however, only three variables remained independently predictive of response: low gamma glutamyltransferase (gamma GT) activities (p < 0.001), absence of obesity (p = 0.005), and absence of cirrhosis (p = 0.01). The response rate in patients with gamma GT activities < 0.66 mu kat/l (n = 55) was 78% and 60% in patients with values > 0.66 mu kat/l (n = 45) (p = 0.048). Response was attained in 75% of non-obese patients (n = 80), compared with only 50% of obese patients (n = 20) (p = 0.03). Finally, 80% of patients without cirrhosis (n = 76) responded, while among those with cirrhosis (n = 24) the response rate was only 37% (p < 0.001). All 23 patients without cirrhosis, <40 years old, and with gamma GT activities <0.66 mu kat/l responded to treatment, while only 28.5% of 14 patients with cirrhosis, >40 years old, and with gamma GT activities >0.66 mu kat/l responded to interferon alfa (p<0.001). Those findings may be useful when evaluating interferon alfa trials and it is suggested that this treatment should be applied early in the course of chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7904252      PMCID: PMC1374469          DOI: 10.1136/gut.34.12.1714

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis?

Authors:  P Marcellin; E Giostra; N Boyer; M A Loriot; M Martinot-Peignoux; J P Benhamou
Journal:  J Hepatol       Date:  1990-07       Impact factor: 25.083

2.  A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies.

Authors:  R Schvarcz; O Weiland; R Wejstål; G Norkrans; A Frydén; U Foberg
Journal:  Scand J Infect Dis       Date:  1989

3.  Experimental colorectal liver metastases. Influence of sex, immunological status and liver regeneration.

Authors:  Y Panis; B Nordlinger; R Delelo; J P Herve; J Infante; M Kuhnle; F Ballet
Journal:  J Hepatol       Date:  1990-07       Impact factor: 25.083

4.  Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia.

Authors:  J Camps; A Castilla; J Ruiz; M P Civeira; J Prieto
Journal:  J Hepatol       Date:  1993-03       Impact factor: 25.083

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Detection and incidence of neutralizing antibodies to interferon-alpha-n1.

Authors:  P K Weck; B G Leventhal; C Brand; N B Finter
Journal:  J Interferon Res       Date:  1989-09

8.  Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France.

Authors:  P Marcellin; N Boyer; E Giostra; C Degott; A M Courouce; F Degos; H Coppere; P Cales; P Couzigou; J P Benhamou
Journal:  Hepatology       Date:  1991-03       Impact factor: 17.425

9.  Impaired monocyte function in liver cirrhosis.

Authors:  A Hassner; Y Kletter; D Shlag; M Yedvab; M Aronson; S Shibolet
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-18

10.  Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors.

Authors:  M G Brook; P Karayiannis; H C Thomas
Journal:  Hepatology       Date:  1989-11       Impact factor: 17.425

View more
  14 in total

1.  Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.

Authors:  M J Walsh; J R Jonsson; M M Richardson; G M Lipka; D M Purdie; A D Clouston; E E Powell
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

2.  Duration of HCV infection as a predictor of nonresponse to interferon.

Authors:  A Craxì; V Di Marco; C Cammà; P Almasio; S Magrin
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

3.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

Authors:  Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakamoto; Yoshiyuki Suzuki; Naoki Hiramatsu; Fuminaka Sugauchi; Hiroshi Yatsuhashi; Namiki Izumi
Journal:  J Gastroenterol       Date:  2010-09-10       Impact factor: 7.527

5.  Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.

Authors:  J M Sánchez-Tapias; X Forns; S Ampurdanés; L Titó; R Planas; J M Viver; D Acero; M Torres; P Mas; R Morillas; M Forné; J Espinós; J M Llovet; J Costa; E Olmedo; F X López-Labrador; M T Jiménez de Anta; J Rodés
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

6.  Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.

Authors:  N P Lam; D Pitrak; R Speralakis; A H Lau; T E Wiley; T J Layden
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

7.  Amantadine therapy for chronic hepatitis C.

Authors:  Jill P Smith; Thomas R Riley; Attila Devenyi; Sandra I Bingaman; Allen Kunselman
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

Review 8.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

9.  IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C.

Authors:  Y Kishihara; J Hayashi; E Yoshimura; K Yamaji; K Nakashima; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

10.  A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.

Authors:  Muhammad Idrees; Sheikh Riazuddin
Journal:  BMC Gastroenterol       Date:  2009-01-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.